XFOR
X4 Pharmaceuticals Inc.
$4.14
+$0.11(+2.73%)
48
Overall
60
Value
50
Tech
36
Quality
Market Cap
$377.28M
Volume
296.34K
52W Range
$1.35 - $4.83
Target Price
$11.67
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | $3.5M | $14.0K | $3.0M | $196.0K | $196.0K | $195.0K | $2.6M | $35.1M | ||
| Total Revenue | $3.5M | $14.0K | $3.0M | -- | $196.0K | $195.0K | $2.6M | $35.1M | ||
| COST OF GOODS SOLD | ||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | $797.0K | $5.8M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | $3.5M | $14.0K | $3.0M | -- | $196.0K | $195.0K | $1.8M | $29.4M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $29.1M | $51.7M | $62.9M | $85.1M | $87.6M | $107.5M | $143.2M | $116.2M | ||
| Research & Development | $20.3M | $30.2M | $41.9M | $50.6M | $61.1M | $72.0M | $81.6M | $72.7M | ||
| Research Expense | $20.3M | $30.2M | $41.9M | $50.6M | $61.1M | $72.0M | $81.6M | $72.7M | ||
| Selling, General & Administrative | $8.7M | $17.6M | $20.9M | $24.7M | $27.0M | $35.5M | $61.5M | $43.5M | ||
| General & Administrative Expenses | $8.7M | $17.6M | $20.9M | $24.7M | $27.0M | $35.5M | $61.5M | $43.5M | ||
| Salaries & Wages | $-759.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-103.0K | $103.0K | $351.0K | $499.0K | $513.0K | $419.0K | -- | -- | ||
| Depreciation & Amortization | $-103.0K | $592.0K | $351.0K | $499.0K | -- | -- | -- | -- | ||
| Amortization | -- | $27.1M | $27.1M | $17.4M | $17.4M | $17.4M | $17.4M | -- | ||
| Other Operating Expenses | $-49.4M | $949.0K | $1.4M | $2.1M | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-29.1M | $-51.7M | $-59.9M | $-85.1M | $-87.6M | $-107.5M | $-36.4M | $-86.9M | ||
| EBITDA | $-32.5M | $-50.6M | $-58.9M | $-84.5M | $-89.3M | $-94.9M | $-27.6M | $-69.0M | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | $3.7M | $2.1M | $2.7M | $3.6M | $4.0M | $5.8M | $8.8M | $8.9M | ||
| Intinc | $236.0K | $1.2M | $273.0K | $10.0K | $219.0K | $4.6M | $5.8M | $4.6M | ||
| Net Non-Operating Interest Income/Expense | $-3.5M | $-950.0K | $-2.4M | $-3.6M | $-3.8M | $-1.2M | $-3.0M | $-4.3M | ||
| Gain on Sale of Securities | -- | $183.0K | $-437.0K | $-366.0K | $1.7M | $7.1M | $1.9M | $12.8M | ||
| Other Income/Expense | $3.6M | $4.1M | $-306.0K | $-60.0K | $-2.0M | $-7.6M | $-107.3M | $-12.0M | ||
| Other Special Charges | $-3.6M | $-4.2M | $743.0K | $426.0K | $-3.7M | $554.0K | $105.3M | $-753.0K | ||
| SPECIAL ITEMS | ||||||||||
| Restructring And Mn A Income | $76.2M | $57.8M | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $-76.2M | $-57.8M | -- | $-9.8M | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | $9.8M | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-32.6M | $-50.7M | $-59.3M | $-85.0M | $-89.8M | $-95.3M | $-28.4M | $-70.3M | ||
| Pre-Tax Income | $-36.3M | $-52.8M | $-62.0M | $-88.7M | $-93.8M | $-101.1M | $-37.1M | $-79.2M | ||
| INCOME TAX | ||||||||||
| Tax Provision | -- | -- | $148.0K | $17.0K | $28.0K | $78.0K | $310.0K | $41.0K | ||
| NET INCOME | ||||||||||
| Net Income | $-36.3M | $-52.8M | $-62.1M | $-88.7M | $-93.9M | $-101.2M | $-37.5M | $-79.2M | ||
| Net Income (Continuing Operations) | $-36.3M | $-52.8M | $-62.1M | $-88.7M | $-93.9M | $-101.2M | $-37.5M | $-79.2M | ||
| Net Income (Discontinued Operations) | $-36.3M | $-52.8M | $-62.1M | $-88.7M | $-93.9M | $-101.2M | $-37.5M | $-79.2M | ||
| Net Income (Common Stockholders) | $-36.3M | $-53.4M | $-62.1M | $-102.6M | $-96.4M | $-101.2M | $-37.5M | $-79.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-78.4M | ||
| TOTALS | ||||||||||
| Total Expenses | $29.1M | $51.7M | $62.9M | $85.1M | $87.6M | $107.5M | $144.0M | $122.0M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $79.5K | $384.3K | $669.2K | $858.3K | $2.1M | $5.9M | $6.7M | $42.3M | ||
| Average Shares Outstanding (Diluted) | $79.5K | $384.3K | $669.2K | -- | $2.1M | $5.9M | $6.7M | $42.3M | ||
| Shares Outstanding | $81.4K | $537.8K | $579.5K | $1.0M | $4.1M | $5.6M | $5.8M | $90.9M | ||
| Basic EPS | -- | $-138.9 | $-92.7 | $-119.7 | $-45.6 | $-17.1 | $-5.7 | $-1.87 | ||
| Basic EPS (Continuing Operations) | -- | $-138.9 | $-92.7 | $-119.7 | $-45.6 | $-17.1 | $-5.7 | $-1.87 | ||
| Diluted EPS | $-541.8 | $-138.9 | $-92.7 | $-119.7 | $-45.6 | $-17.1 | $-5.7 | $-1.87 | ||
| Diluted EPS (Continuing Operations) | $-541.8 | -- | -- | -- | $-45.6 | $-17.1 | $-5.7 | $-1.87 | ||
| OTHER METRICS | ||||||||||
| Accrued Preferred Stock Dividends | $22.0K | -- | -- | $13.9M | -- | -- | -- | -- | ||
| Acquisition Expense | -- | $592.0K | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $8.7M | $17.6M | $20.9M | $24.7M | $27.0M | $35.5M | $61.5M | $43.5M | ||
| Preferred Stock Dividends | $22.0K | -- | -- | $13.9M | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-1.3M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | $76.2M | $57.8M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | XFOR | $4.14 | +2.7% | 296.34K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |